News

CURE8d
Enhertu Regimen Improves Responses in High-Risk HER2+ Breast Cancer
Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...
pharmaphorum9d
New data could move Enhertu into early breast cancer
AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...
Fierce Pharma8d
AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...
Applied Clinical Trials Online8d
DESTINY-Breast11 Trial Shows Enhertu Plus THP Significantly Improves Response Rates in High-Risk HER2-Positive Early Breast Cancer
Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...
PharmiWeb9d
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...
Clinical Trials Arena on MSN8d
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...
PMLive8d
AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...